Inclusion Criteria:  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Patients must have cytologically or histologically confirmed advanced malignant tumor, and must have failed standard treatment; Toxicities caused by prior anti-tumor treatments must have resolved to CTCAE Grade ≤ 1 prior to the first dose (except for alopecia or hypothyroidism treated with hormone replacement therapy or diabetes controlled with insulin); Adequate organ function.  Exclusion Criteria:  With CNS infiltration, or ascites requiring paracentesis or symptomatic pleural effusion; Received prior CAR T-cell therapy; Received allogeneic hematopoietic stem cell transplantation within 3 months prior to the start of study treatment, or with acute/chronic graft versus host disease; With active infection or fever of unknown origin (> 38.5 °C).